Post-hoc analysis of addition of venetoclax to induction chemotherapy for newly diagnosed AML

Venetoclax compared with intensive induction chemotherapy has been shown to be safe with promising activity in fit patients with newly diagnosed acute myeloid leukemia. A post-hoc propensity score matched analysis of prospective clinical trials compared this combination with intensive chemotherapy alone. The combination resulted in a higher percentage of patients with MRD-negative complete response, higher incidence of allogeneic HSCT in responding patients, and improvement in event-free survival.